Thailand Oral Anti Diabetic Drug Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Thailand's oral antidiabetic drug market represents a critical segment of the country's pharmaceutical sector, anchored by a diabetic population that has grown steadily since 2004 according to Thai National Health Examination Survey data. Oral medications, including biguanides, sulfonylureas, DPP-4 inhibitors, and other glucose-lowering agents, form the backbone of type-2 diabetes treatment, with combination therapy being the norm rather than the exception.

• •Market valued at approximately $0.11 billion in 2025
• •41.22% of type-2 diabetes patients use at least two oral antidiabetic drugs concurrently
• •Metformin and sulfonylurea combinations account for roughly 96% of the oral market share

Rising diabetes prevalence among Thai adults, documented through national health surveys tracking trends from 2004 to 2020, fuels consistent demand for oral antidiabetic therapies. The Universal Coverage Scheme acts as a powerful enabler by subsidizing drug access for the majority of the population, while the high rate of multi-drug regimens, many patients require add-on therapies to metformin, sustains recurring prescription volumes across public and private channels.

• •Epidemiological data shows a long-term upward trend in adult diabetes prevalence through 2020, supporting continued demand through 2025-2030
• •Thailand's Universal Coverage Scheme broadens patient access to essential oral antidiabetics like metformin and glipizide across public hospitals
• •High intensification rates, patients adding agents to metformin, drive multi-drug consumption and market expansion

Within the oral class, biguanides (metformin) and sulfonylureas such as glipizide remain the dominant segments, together capturing the vast majority of prescriptions. DPP-4 inhibitors represent a growing niche, increasingly used as add-on therapy for patients inadequately controlled on metformin monotherapy. Regional access and pricing are shaped by the National Health Security Office's public hospital procurement framework, which influences availability and price trends across Thailand's provinces.

• •Metformin and sulfonylureas hold approximately 96% of oral antidiabetic market share, with DPP-4 inhibitors as an emerging secondary segment
• •Public hospitals under the National Health Security Office are the primary distribution channel for essential oral antidiabetics
• •Real-world data from tertiary care hospitals shows metformin-sulfonylurea combination as the most common intensified treatment regimen

What are the recent trends and outlook?

The market is expected to maintain a steady compound annual growth rate of approximately 3.79%, supported by ongoing diabetes epidemiology and policy-driven access. A notable trend is the shift toward combination oral therapies and the incremental uptake of newer drug classes, even as metformin and sulfonylureas remain dominant. Healthcare expenditure on diabetes, including direct costs of oral medications and associated hospital visits, remains a significant national budget consideration, reinforcing the market's structural resilience.

• •3.79% CAGR projected through the forecast period, driven by rising prevalence and treatment intensification
• •Gradual adoption of newer oral agents such as DPP-4 inhibitors as add-on therapies supplements the metformin-sulfonylurea base
• •Direct healthcare expenditures on oral antidiabetics and hypoglycemia-related hospital visits represent a substantial national financial burden, sustaining policy and market attention